Sign In
Buy BNTX
$88.45
-0.690 (-0.774%)
At Close: Jun 03, 2026
BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
06:45am, Tuesday, 21'st May 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company's diversified immuno-oncology p
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
04:00am, Tuesday, 21'st May 2024
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiat
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports
12:00pm, Friday, 17'th May 2024
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its COVID-19 vaccine, the Financial Times reported on Friday.
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
11:15am, Friday, 17'th May 2024
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per
BioNTech SE (BNTX) Q1 2024 Earnings Call Transcript
12:30pm, Monday, 06'th May 2024
BioNTech SE (NASDAQ:BNTX ) Q1 2024 Earnings Conference Call May 6, 2024 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CEO Ozlem Tureci - Chief Medical
BioNTech's Outlook Gives Vaccine Maker a Shot in the Arm
11:25am, Monday, 06'th May 2024
American depositary receipts (ADRs) of BioNTech (BNTX) were down less than 1% in intraday trading Monday after the COVID-19 vaccine maker shrugged off losses and tumbling sales in the first quarter,
BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
08:57am, Monday, 06'th May 2024
BioNTech stock fell early Monday after the German biotech reported wider-than-expected losses and short Covid vaccine sales.
BioNTech Revenue Falls Sharply on Reduced Covid Vaccine Sales
07:31am, Monday, 06'th May 2024
The pharmaceutical company posts a first-quarter loss of €1.31 a share, a swing from year-earlier profit of €2.05.
BioNTech says 90% of 2024 revenues will accrue at end of year
06:52am, Monday, 06'th May 2024
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
06:45am, Monday, 06'th May 2024
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-
Why Earnings Season Could Be Great for BioNTech (BNTX)
11:11am, Friday, 03'rd May 2024
BioNTech (BNTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BioNTech (BNTX) to Report Q1 Earnings: Is a Beat in Store?
01:00pm, Tuesday, 30'th Apr 2024
On BioNTech's (BNTX) first-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its pipeline development now that the pandemic is over.
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
09:40am, Thursday, 25'th Apr 2024
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-1
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
06:45am, Monday, 22'nd Apr 2024
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2
MAINZ, Germany, April 7, 2024 - BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neo
